Leading Antipsychotic Drugs Come Under New Scrutiny – NYT Tuesday, May 20, 2003 A front page article in The New York Times reveals that the pillars of American psychiatry–including Dr. Jeffrey Lieberman, Dr. John Kane, Dr. William Carpenter–are acknowledging that evidence is lacking to support the claims that the new…
TeenScreen: Who Pays for Treatment and Drugs?? Sun, 29 May 2005 In her latest examination of the President’s Commission on Mental Health recommendation for universal mental health screening, Evelyn Pringle focuses on the $$$ it costs and on how screening, followed by prescribing psychotropic drugs, is bankrupting of public health…
“Schizophrenia Digest” Canadian magazine Tue, 3 Jun 2003 Behold the new marketing promo in the guise of “Inspiration and information”….”Schizophrenia Digest” is touted as a magazine directed at schizophrenia patients and families. The publisher, William J. MacPhee, who claims he is taking an antipsychotic, says, “My personal philosophy is that…
Drugmakers Go Furthest to Sway Congress: 1,274 Lobbyists – USA Today Tue, 26 Apr 2005 USA Today provides a glimpse into the way the pharmaceutical industry controls health care policy by buying influence at the highest level of government, and underwriting professional and lay healthcare organizations whose spokespersons parrot industry’s…
Forbes: Judgment Day for the FDA, Pfizer Wed, 9 Feb 2005 On Feb. 16-18 COX-2 Inhibitor Safety Issues will be the focus of an FDA Advisory Committee and (simultaneously) the European Medicines Agency (EMA). The entire drug industry will be watching with bated breath. Which causal explanation will be offered…
10 of 32 FDA Vioxx Panelists Had Industry Ties_NYT / Cozy NIH Review “Clears” NIH Industry Ties_WashPost Fri, 25 Feb 2005 The latest example of the corrupting influence of the pharmaceutical industry on health care policy is the composition of FDA’s advisory panel that last week endorsed the marketing of…
The risks of the drugs far outweigh their benefits, said Vera Sharav, president of the Alliance for Human Research Protection, a New York-based consumer advocacy group.
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
Psychiatry’s most powerful and influential key opinion leaders who belong to the American College of Neuropsychopharmacology (ACNP) have been caught off guard. The ACNP leadership is scrambling to overcome the scorn it has received following public disclosure about multiple breaches of ethics and professional standards of conduct. The College and…
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
An editorial in today's New York Times is a follow-up to its riveting report by Ian Urbina on the recommendation by an Institute of Medicine panel to
lift 1978 federal restrictions on medical experiments on prisoners. http://www.nytimes.com/2006/08/13/us/13inmates.html?
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
